Table 4 Primary and secondary outcomes between the cancer therapy-related cardiac dysfunction (CTRCD) group and the non-CTRCD group.
From: Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
CTRCD (N = 36) | Non-CTRCD (N = 38) | p | |
|---|---|---|---|
Primary endpoints (i.e. all-cause mortality and heart failure) | 12 (33%) | 4 (11%) | 0.03 |
All-cause mortality | 8 (22%) | 3 (8%) | 0.15 |
Heart failure | 7 (19%) | 3 (8%) | 0.13 |
Secondary endpoints | |||
CTCAE HF score | |||
Post-treatment 3 cycles | 0.0 ± 0.2 | 0.1 ± 0.4 | 0.44 |
Post-treatment 6 cycles | 0.4 ± 0.8 | 0.3 ± 0.7 | 0.43 |
Post-treatment 1 year | 0.3 ± 0.7 | 0.5 ± 1.0 | 0.47 |
